Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.
Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.
Hyperfine (Nasdaq: HYPR) will host an analyst and investor education webcast on June 25, 2024, at 2:00 PM ET, focusing on advancements in ultra-low-field (ULF) MR imaging.
Led by Dr. Edmond Knopp, VP of Medical Affairs, the event features key opinion leaders (KOLs) discussing the Swoop® portable MR imaging system's application in critical care, stroke, and dementia, including Alzheimer's workflows.
Guest speakers include Dr. Jamal Derakhshan from Jefferson Abington Hospital, Dr. W. Taylor Kimberly from Mass General Hospital, and Dr. Cyrus A. Raji from Barnes Jewish Hospital. The webcast will end with an interactive Q&A session. The live audio and an archive of the webcast will be accessible on Hyperfine's investor relations page.
Hyperfine (Nasdaq: HYPR) is expanding its global reach by partnering with Radiosurgery Global to distribute its portable MR imaging system, Swoop®, in India. This strategic move addresses India's significant shortage of MRI scanners, with fewer than 5,000 units for over 1.4 billion people. The Swoop® system is designed to enhance diagnostic capabilities, particularly in underserved critical care and emergency settings. Hyperfine also plans future expansions into Malaysia, Indonesia, and Singapore. The company’s expansion is bolstered by recent certifications in the EU and UK and aims for regulatory approval in India through CDSCO. This collaboration signifies a major step toward improving healthcare accessibility and patient outcomes across Asia.
Hyperfine, a health technology company known for its FDA-cleared portable MR brain imaging system, the Swoop®, will present at the Jefferies Global Healthcare Conference in New York on June 6, 2024, at 3:00 pm ET. The event will be live-streamed and archived on the company's investor relations website for 90 days. For more details about the Swoop® system, visit their official website.
Hyperfine (Nasdaq: HYPR) participated in the 2024 ASNR Annual Meeting held in Las Vegas from May 18-22, 2024. The event highlighted the use of the Swoop® Portable MR Imaging® system, particularly for Alzheimer's care. Presenters emphasized the critical role of MRI in diagnosing and managing Alzheimer's disease and the potential of portable MR imaging to fill existing gaps in diagnostic capabilities. Sessions focused on the importance of monitoring amyloid-related imaging abnormalities (ARIA) for safe Alzheimer’s treatments. Attendees expressed significant enthusiasm for the Swoop® system’s benefits in clinical settings.
Hyperfine (Nasdaq: HYPR) announced its Q1 2024 financial results on May 13, 2024. The company reported $3.30 million in revenue, a 25% increase from Q1 2023, and sold 13 Swoop® systems. Gross margin improved to $1.35 million. R&D expenses were $5.57 million, and SG&A expenses dropped to $6.43 million. Net loss decreased to $9.85 million ($0.14 per share) from $12.16 million ($0.17 per share) in Q1 2023. Key milestones include starting the CARE PMR Alzheimer’s study, enrolling over 100 patients in the ACTION PMR stroke study, and launching the 8th-gen AI-powered software. Full-year 2024 revenue is expected to be $12-$15 million with a $40 million cash burn.
Hyperfine, Inc. (Nasdaq: HYPR) has appointed distributors in France, the UK, and Italy to expand the market reach of its portable MR brain imaging system, Swoop®. The company has obtained CE certification and UKCA certification for its latest hardware and AI-powered software. The move aims to meet the global demand for accessible MR brain imaging, with a focus on Alzheimer's disease and acute stroke applications. Enrico Barini joins as International Business Development Director to lead the European market expansion.
Hyperfine, Inc. (Nasdaq: HYPR) will announce its first quarter 2024 financial results on May 13, 2024. The company, known for its FDA-cleared portable MR brain imaging system, the Swoop® system, will host a conference call on the same day. The event can be accessed via the Investors page of Hyperfine, Inc.'s website.
Summary not available.
Summary not available.
Summary not available.